People treated for aggressive melanoma now have a concrete reason to watch a single experimental combination closely. In a ...

For most of the past three years, Jim Cramer kept his distance from Moderna, treating the biotech stock with skepticism bordering on avoidance. The Cambridge, Massachusetts, company had become ...

From space to healthcare and artificial intelligence, what could the next 250 years of the United States look like?

Moderna ( MRNA +10.01%) stock jumped about 10% on Thursday to $79.76 -- a fresh high for the year and the latest leg of a run ...

Moderna surges 33.5% after the company outlines plans to expand its mRNA platform beyond vaccines into oncology, autoimmune diseases and cell therapies.

Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and ...

Many of the FDA’s decisions this quarter involve applications that have previously been delayed, declined or outright ...

The FDA advisory panel unanimously supported mRNA-1010/mFLUSIVA for adults 50–64 and 65+, and the stock is already reacting ...

To date, the company has raised over $34 million from investors and operates a 15-person team at facilities at Johns Hopkins Medical Campus.

Billions of doses later, a global review has found that mRNA vaccines are safe and highly effective. Not only have they ...

A recent survey suggests that using apps and artificial intelligence for health advice may be linked to vaccine distrust.